55
Participants
Start Date
January 13, 2025
Primary Completion Date
March 31, 2026
Study Completion Date
March 31, 2026
LASSARAB+ aPHAD-SEat 700rU
Rabies-Vectored Monovalent Lassa Fever Vaccine (LASSARAB) with 3D-(6- acyl) Phosphorylated Hexaacyl Disaccharides (PHAD)-Stable squalene oil-in-water nanoemulsion (aPHAD-SE) adjuvant administered by IM injection
HDCV Comparator
Sterile, stable, freeze-dried suspension of rabies virus prepared from strain PM-1503-3M
Normal Saline Placebo
Sterile 0.9% sodium chloride for injection, USP, or normal saline, is a sterile, nonpyrogenic, isotonic solution; each mL contains sodium chloride 9 mg
LASSARAB+ aPHAD-SEat 1400rU
Rabies-Vectored Monovalent Lassa Fever Vaccine (LASSARAB) with 3D-(6- acyl) Phosphorylated Hexaacyl Disaccharides (PHAD)-Stable squalene oil-in-water nanoemulsion (aPHAD-SE) adjuvant administered by IM injection
University of Maryland, Baltimore, University of Maryland School of Medicine, Center for Vaccine Development and Global Health, Baltimore
Wilbur Chen, MD, MS
OTHER